Thank you for registering with Multiple Sclerosis News Today’s Clinical Trial Registry.
We will inform you of new clinical trials as information becomes available.
In the meantime, feel free to access these other MS-related resources:
- Umbilical Cord Stem Cells Work to Restore Immune System Balance in Early Study
- Relapses and Dislike of Needles Among Reasons MS Patients Stop Betaferon Treatment
- RedHill Awaits Patent for RHB-104, Potential MS Treatment, from Japan
- Tysabri May Be More Effective Than Gilenya at Reducing Disease Activity in MS Patients, Study Says
- MS Trust to Oppose NICE Plan to Reject Zinbryta as MS Therapy in Health System for England, Wales
- #ECTRIMS2016 – Treatment for Relapsing MS, Ozanimod, Shows Efficacy in 2-Year Extension of Phase 2 Study
- #ECTRIMS2016 – Gilenya Study Shows Long-term Benefits for MS Patients
- #ECTRIMS2016 – Novartis’s Siponimod Appears to Slow SPMS Progression in Phase 3 Study
- #ECTRIMS2016 – Antioxidant Lipoic Acid Appears to Slow SPMS Patients’ Neurodegeneration
- #ECTRIMS2016 – Brain MRI Scans Can Predict Which Patients Will Progress into SPMS
- #ECTRIMS2016 – Inflammatory Profiles of Brain Seen to Predict MS Disability
- Gilenya-like Therapy Shows Benefit in Secondary Progressive MS Patients in Phase 3 Trial
- Phase 2 Study of Oral Antibiotic to Treat Relapsing MS, RHB-104, Nearing Finish
- New Zealand Clinical Trial to Test Potential of Antipsychotics to Treat SPMS
- #ECTRIMS2016 – Modeling Approach Able to Identify Likely Disease Trajectory in Progressive MS Patients
- #ECTRIMS2016 – New Data Show Ocrevus Effective in Treating Primary and Relapsing MS
- Riding the High-Dose Biotin Train for Progressive MS
- Don’t Let Your MS Bully You!
- Is Your Neurologist Listening to What Your MS Is Saying?
- Genentech Enrolling Relapsing MS Patients in Study of Mechanism of Action for Ocrevus
- 1st Potential Therapy for Primary Progressive MS, Ocrelizumab, Under Priority Review by FDA